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Hospital Universitari i Politècnic La Fe 
Spain 
1. Introduction 
The gut, due to its anatomical and functional characteristics, forms the largest area of contact 
with the outside world. Unlike skin that acts as a defensive barrier, digestive and absorptive 
processes in the intestine require a certain amount of permeability. This facilitates and 
creates an optimal niche for the development of a large community of microorganisms that 
maintains, ideally, a commensal relationship with the host. This ecosystem, known as 
microbiota, is essential for the digestion of certain carbohydrates, the production and 
metabolism of nutrients necessary for life and for proper development and maturation of 
the immune system.  
The aim of this chapter is to offer a thorough review of recent publications and scholarly 
work in order to explain, and somehow clarify, the always complex interaction between 
humans and microorganisms, as well as the implications that the later have in Ulcerative 
Colitis. 
1.1 The human microbiota 
Should we consider the number of microorganisms that live in the mucous linings of human 
beings, we should be considered merely as the base that supports and nourishes a large 
microbial ecosystem. Indeed, the total amount of bacteria that colonize our gut reaches 
about 100 trillion, while the number of cells in our body is no more than 10 trillion. The 
physiological and environmental differences of each part of the body determine the 
existence of many different niches, each with its unique microflora adapted to the 
nutritional resources, pH and presence of antibacterial substances. The capabilities inherent 
to the colonizing organisms such as the presence of pili or fimbriae which facilitate 
adherence to epithelial cells, the specific metabolic pathways that each genus is able to 
develop or the cell wall components that confer increased resistance to the environment are 
also vital. 
The large intestine is by far the location with the greatest number of microorganisms which 
establish a symbiotic relationship that is broadly beneficial to the host. Over 98% of the 
microbiota that is found past the ileocaecal valve consists of strict anaerobes, outnumbering 
aerobic bacteria in a ratio of 1/1,000- 1/10,000. Numerous studies performed hitherto 
describe microbiota as having between 200 and 1,000 different species of bacteria in healthy 
subjects any given time, with horizontal transmission of genetic material between species. 
This means that there is great diversity among the microbiota of different people, and that 
there is no common core related to all humans, since no particular species is more than 1% 
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of the total. Only about 50-100 bacteria were found in most individuals regardless of their 
number. On the other hand, it has been observed that the changes that occur over the 
lifetime of a healthy person are minimal, the most dramatic being at the beginning of life, 
since initial colonization after birth until weaning, when the microbiota begins to transform 
and becomes gradually very similar to that of an adult. These changes are determined by the 
geographic location with their characteristic eating habits, by the type of birth (caesarean 
versus vaginal delivery), and the type of feeding after birth (breast vs. bottle). Eventually, 
the microbiota is composed mostly (> 90%) by bacteria of the genera Bacteroides and 
Bifidobacterium, and the rest by Eubacterium, Lactobacillus, coliforms, Streptococcus, 
Clostridium, and a variable number of yeasts. 
As an indirect consequence of the large number and variety of microorganisms, the balance 
achieved between the components of the microbiota and the competition for nutritional 
resources exert a protective effect on the host by preventing colonization and proliferation of 
potential pathogens. 
This huge set of microorganisms contains approximately three million of unique genes, i.e. 
150 times more genes than our own genome. This metagenome or microbiome is essential 
for proper homeostasis and good health, as it provides metabolic pathways that allow 
implementations that we would be unable to perform without the assistance of the intestinal 
microbiota, like digestion of some sugars, production of vitamins or removal of hydrogen in 
the distal intestine. Recent studies have demonstrated a common set of around 500,000 
unique genes shared by the microbiota of different subjects, in other words, a common 
metagenome. For all this, it has been suggested that the microbiota serves as an organ for 
human beings (Zhu et al., 2010). 
In addition to these functions, the intestinal epithelium requires intestinal flora and the 
substances excreted by it in order to develop properly, given that these metabolic by-
products promote growth and epithelial differentiation. 
1.2 Microbiota and immune system 
The intestinal lumen is comparable to a battlefield; there is a continuous struggle even when 
the host does not show any type of pathology. Indeed, the intestinal epithelium is 
extensively infiltrated by lymphocytes with defensive functions. More profoundly, in the 
lamina propria, dendritic cells are responsible for monitoring the presence of pathogenic 
antigens and activate surrounding lymphocytes if necessary. It has been established that 
there is a continuous exchange of information and regulation between epithelial and 
immune cells present in the intestinal mucosa, mainly through Toll-like receptors on the cell 
membrane and the Nucleotide-binding oligomerization domains in the cell cytosol, but also, 
by other substances that need further investigation so their functioning is utterly 
understood. The end result of this cross-talk is the development and maturation of 
lymphocytes Th 1, Th 2, Th 17 (a type of lymphocyte abundant in the intestine but scarce 
elsewhere in the body), regulatory T cells, IgA-secreting plasma cells and the release into the 
intestinal lumen of bactericidal substance like the defensins (Tanoue et al., 2010; Sansonetti , 
2010). All this leads to the subsequent inflammatory response or tolerance reaction; but also 
to systemic immune defence maturation, as neutrophils, in the absence of intestinal flora, 
lack the necessary priming to be effective (Takeshi et al., 2010). 
Several studies have shown that a plural and abundant microbiota is essential to maintain a 
balance between defensive immune responses and tolerance towards commensal bacteria 
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(Salzman, 2010; Tanoue et al., 2010; Lidar et al., 2009). But some bacteria seem to have a 
more significant role than others: 
- Segmented Filamentous Bacteria, a Gram-positive bacteria related to Clostridium, also 
known as Candidatus arthromitus, is capable by itself of stimulating the differentiation of 
Th 17 cells, which by producing IL-17 attracts neutrophils and macrophages to the gut 
mucosa. But on the other hand, these bacteria also stimulate the IgA-producing plasma 
cells, an antibody that blocks bacterial antigens in the intestinal lumen and prevents the 
possible infiltration and local inflammation while regulating the ecological balance of 
the commensal flora. This bacterium is not found in the mucus above the epithelial 
layer, instead, it attaches intimately to the epithelial cells (Takeshi et al., 2010). 
- A Gram-negative bacterium, Bacteroides thetaiotaomicron, whose presence down-
regulates inflammation by activation of the nuclear export of RelA, subunit of Nuclear 
Factor kappa B, a substance with inflammatory properties that enhances gene 
transcription when located inside the nucleus (Takeshi et al., 2010). This protein 
complex is related to the receptor responsible for the anti-inflammatory properties of 5-
aminosalicylic acid. 
- Two species of Gram-positive rods, Lactobacillus spp. and Bifidobacterium spp., and a 
Gram-negative rod, Bacteroides fragilis, induce the maturation of regulatory T cells in the 
lamina propria, stimulating the production of IL-10, an immunosuppressive interleukin 
(Danase, 2011; Takeshi et al., 2010). 
1.3 Microorganisms as causative agents in ulcerative colitis 
Since the description of inflammatory bowel disease as an independent clinical entity, 
attempts have been made to associate it with a particular microorganism as an aetiological 
agent, as happened with Helycobacter pylori and gastric ulcer. Several studies have shown 
some involvement of a number of pathogens in the onset of Ulcerative Colitis flares, but to 
date, no study has concluded a positive relation between a microorganism and this disease: 
- Cytomegalovirus and Clostridium difficile are able to develop a condition similar to 
Ulcerative Colitis, precipitate a relapse or worsen the course (Lawlor et al., 2010; 
Sonnenberg, 2010). In addition, it has been found a linear geographical relationship 
between Ulcerative Colitis cases and colitis due to C. difficile. 
- Escherichia coli, Campylobacter jejuni, Salomonella enterica and Shigella spp. have been 
associated with this disease because of their ability to disrupt the intestinal epithelium, 
promote a displacement of commensal flora and trigger an excessive inflammatory 
response (Gasull et al., 2007; Phalipon & Sansonetti, 2003; Siegel et al.,2005). 
- Mycobacterium avium paratuberculosis has been associated with Crohn's disease, but some 
studies suggest it may have some relevance in patients with impaired intracellular 
bacteria destruction by a continuous augmented state of inflammation. 
The most recent lines of research point to the dysbiosis as the cause of up-regulated 
inflammation. Several studies have discovered that the microbiota of Ulcerative Colitis 
patients is significantly different from that of healthy controls (Danase, 2011; Scarpa et al., 
2011). Although, a causal relationship was not establish because these changes in the 
microbiota could be either the cause or the consequence of the alterations observed in the 
intestinal epithelium. Thus far, this hypothesis is to some extent supported by some other 
studies that point toward the transplant of healthy microbiota as a solution to the disease, 
with very promising results (Do et al., 2010; Kahn et al., 2011; Ng et al., 2010). 
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The main theories that try to explain Ulcerative Colitis aetiopathogenesis by means of an 
infectious agent can be summarized as follows: 
- Dysbiosis hypothesis which implies that an imbalance between beneficial versus 
detrimental resident intestinal bacterial species may incite chronic inflammatory 
responses (Friswell et al. 2010). 
- Persistent infection hypothesis which proposes that Ulcerative Colitis may arise as a 
result of persistent infection with enteric pathogens (Khan et al., 2011). 
- Luminal antigen translocation hypothesis which indicates that defects in the intestinal 
barrier function or impaired mucosal clearance facilitate increased translocation of 
luminal antigens, including intestinal commensal bacteria, across the intestinal barrier 
where they may prime mucosal immune responses that lead to loss of immunological 
tolerance toward the luminal antigens (Fava & Danes, 2011). 
- Hygiene hypothesis which postulates that helminthic colonization of the gut shifts 
immune response towards Th 2 and Th 3, i.e., humoural and regulatory pathways. 
Thus, prevention of parasitic helminths by means of improved hygiene, may be one 
factor leading to Ulcerative Colitis through a excessive Th 1 immune response 
(Weinstock & Elliot, 2008). 
In summary, the relationship between the microbiota and its host is very complex and 
studies to date suggest that the aetiology of Ulcerative Colitis is equally complex. Beyond 
the characteristics of the patient, a myriad of microorganisms capable of modulating the 
inflammatory response come into play. To find a single responsible among them challenges 
conventional models of infectious disease, and small variations in the concentration or 
location of commensal microorganisms may be the key. 
2. Immunosuppressive therapy in ulcerative colitis 
Immunosuppressive drugs are used increasingly and earlier for the treatment of Ulcerative 
Colitis. This implies an important risk factor for these patients since they become partially 
defenceless against possible microbiological pathogens. Moreover, the degree of 
immunosuppression may be exacerbated by factors such as older age (Cottone et al., 2010), 
severity of symptoms and comorbidities, recent surgery or malnutrition. In addition, more 
severe conditions or those that do not respond to treatment involve a greater degree of 
immunosuppression due to the fact that the combination of two or more drugs is required 
(Koutroubakis, 2010). Table 1 summarizes immunosupression impairments and the most 
common microorganisms associated. 
2.1 Corticosteroids 
Corticosteroids suppress the Th 1 response by inhibiting the transcription of genes encoding 
pro-inflammatory interleukins, chiefly IL-2; thereby reducing the proliferation and 
activation of T cells. However, the Th 2 response is also altered, given that B lymphocytes 
express fewer IL-2 receptors and consequently, there is a reduction in the production of 
antibodies (Elenkov, 2004). 
This reduction in pro-inflammatory cytokines tampers the chemotactic migration of 
neutrophils to the inflammatory focus, diminishing also its ability to adhere and its 
phagocytic function. 
Phagocytosis of opsonised microorganisms is also disturbed as the expression of FC 
receptors in macrophages is down-regulated too (Franchimont, 2004). 
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Immune response impairment Microorganisms  
Neutropenia 
Staphylococcus aureus, Gram-negative rods, 
Aspergillus, Candida 
Phagocytic function 
Streptococcus  pneumoniae, Haemophilus 
influenzae 
Chemotaxis Sataphylococcus aureus, Mucor 
T lymphocytes (Th 1 response) 
Mycobacterium, Nocardia, Legionella, Aspergillus, 
Candida, Cryptococcus neoformans, Pneumocystis 
jiroveci, Cytomegalovirus, Herpes simplex virus, 
Varicella-Zoster virus, respiratory viruses, 
Strongyloides, Toxoplasma, Leishmania 
B lymphocytes (Th 2 response) 
Staphylococcus aureus , Streptococcus  
pneumoniae, Haemophilus influenzae, 
Pneumocystis jiroveci, Enterobacteriaceae 
Table 1. Immune System impairment and most common associated microorganisms 
2.2 Purine analogues: Azathioprine and 6-mercaptopurine 
Azathioprine is a pro-drug that is converted into 6-mercaptopurine by human metabolism. 
6-thioguanine nucleotides, the resulting metabolites, accumulate in tissues where they exert 
their cytotoxic effects by inhibiting purine synthesis and consequently, DNA and RNA. 
Therefore, a decrease in the production of T and B lymphocytes is achieved; they also 
promote apoptosis of activated T lymphocytes. Thus, both the Th 1 and Th 2 immune 
responses are impaired (Sahasranaman et al., 2008; Tiede et al. 2003). 
The therapeutic effects of these drugs are achieved within 2-3 months from administration, 
and duration of treatment depends on adverse effects and patient's tolerance, so that the 
time period of immunosuppression that the patient will face can be considerable (Maltzman 
& Koretzky, 2003). 
2.3 Calcineurin inhibitors: Tacrolimus and cyclosporine 
Calcineurin inhibitors decrease the cellular immune response by inhibiting T-dependent 
antibody production and several cytokines, chiefly IL-2 but also IL-3, IL-4, IL-5, Tumour 
Necrosis Factor alpha and beta. A reduction in the number of activated T lymphocytes is 
achieved with a significant decrease in the Th 1 response. Numerous studies have shown 
that calcineurin inhibitors can be effective for short-term clinical improvement in patients 
with refractory disease, but also could be used in situations that require an early and 
powerful response as in fulminant Ulcerative Colitis. The use of these drugs requires careful 
assessment of risks and benefits, and close surveillance of adverse effects. 
2.4 Biological therapies  
Biological drugs block the action of Tumour Necrosis Factor alpha, a pro-inflammatory 
cytokine, and promote apoptosis of activated T cells, inhibiting Th 1 immune response and 
local inflammation. Monoclonal antibodies anti-Tumour Necrosis Factor alpha mechanism 
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of action includes the neutralization of both soluble and transmembrane portion of this 
molecule; also neutralizes Tumour Necrosis Factor alpha-producing (Sandborn, 2010; 
Smolen, 2011). Monoclonal antibodies anti-Tumour Necrosis Factor alpha were first used in 
the treatment of Crohn's disease but have been used successfully in severe, unresponsive to 
treatment Ulcerative Colitis or as rescue therapy (Hoentjen & van Bodegraven, 2009; Lees et 
al. 2007).  
3. Ulcerative colitis and infection 
Patients suffering from Ulcerative Colitis may develop infections just like any healthy 
person. However, there are a number of situations and conditions that make these infections 
critical; hence they must be addressed as soon as possible in order to avoid unwanted or 
unexpected complications. 
On the one hand, these patients present an altered immunity, which predisposes them to 
face a number of opportunistic microorganisms that seldom cause disease in healthy people. 
Second, they are challenged with infections from typical and common pathogens, but in 
their state of immunosuppression this microorganisms may have a more aggressive course 
and a worse prognosis (Harbaum et al., 2010; Nagasaki et al., 2010). Local disorders in the 
digestive tract result in another source for potential complications, allowing the 
displacement of bacteria from the normal microbiota which are harmless otherwise 
(Sahuquillo-Arce et al., 2008). Finally, these patients may need surgical treatment, 
aggravating local immunosuppression as well as increasing susceptibility to infection 
(Scarpa et al. 2011). 
Although large studies of patients with Ulcerative Colitis show a low prevalence of 
opportunistic infections, there are numerous articles about specific cases reports or short 
series of such infections, which confirm the severity that these infections can acquired in 
Ulcerative Colitis patients (Aoyagi et al., 1999; Chuang et al., 2010; Escher et al., 2010; Kudo 
et al., 2010; Rodríguez-Peláez et al., 2010). 
An early suspicion of these complications is essential to enhance prognosis in this group of 
patients, so physicians must improve their knowledge and be aware about these infections. 
The management of immunocompromised patient is difficult; therefore, an early diagnosis 
and a prompt establishment of an adequate therapeutic regimen remain the two 
fundamental pillars that will determine the course and outcome of infection. 
3.1 Management of the patient before infection 
The infectious and immunological history of the patient should be defined when Ulcerative 
Colitis is first diagnosed, and whenever possible, before starting immunosuppressive 
therapy (Viguet et al., 2008). This will require a thorough knowledge about the patient and a 
systematic record of every detail (Rahier et al., 2009) in order to assess: 
- The history of past infections and travels to areas with endemic infections, even if those 
travels are distant in time. 
- A methodical review of systems, including regular dental and gynaecological 
evaluation. 
- A serological screening to evaluate the immune status against the following viruses: 
rubella, measles, mumps, Varicella-Zoster, Cytomegalovirus, Epstein-Barr, hepatitis B, 
hepatitis C, HIV, poliovirus; and against tetanus, diphtheria and Toxoplasma gondii. 
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- Any contact with Mycobacterium tuberculosis by means of a chest X-ray and tuberculin 
skin test (with a booster if negative) or interferon-gamma release assays (Schoepfer et 
al. 2009), in patients who have not suffered from tuberculosis in the past. These tests 
should always be performed, but they are mandatory before initiating therapy with 
anti-Tumour Necrosis Factor alpha drugs. 
The use of vaccines is another important step in managing these patients. Besides the 
recommended vaccinations for the general population, the following should also be 
considered (Aberra & Lichtenstein, 2005): 
- Varicella-Zoster in seronegative patients, preferably before starting immunosuppressive 
therapy since this vaccine contains attenuated viruses. Passive immunization should be 
considered in seronegative high risk immunosupressed patients after exposure to the 
virus. 
- Pneumococcal vaccination with booster after 3-5 years. 
- Hepatitis B, which may require a booster due to immunosuppressive therapy. 
- Influenzavirus annually. 
- Papillomavirus in young women, according to national guidelines. 
- Travel vaccines; the practitioner must bear in mind that vaccines which contain live 
viruses should be avoided. 
3.2 Management of patients with suspicion of infection 
The diagnosis of infection begins with a thorough anamnesis, which should reflect the 
degree and time length of immunosuppression of the patient, concomitant diseases, use of 
antineoplastic or antimicrobial treatments, presence of catheters, previous infections and 
any possible exposure to nosocomial, occupational or unusual pathogens, such as travels to 
endemic areas of histoplasmosis, coccidioidomycosis, etc. These factors will be crucial in 
establishing an empirical treatment (Gómez Gómez & Gobernado, 2011). 
A systematic physical examination will be the next step. Given that very often the symptoms 
that immunosuppressed patients present are scarce or absent, and that fever can be the only 
one, the physician's attitude should be aggressive in order to locate the source of infection. 
To describe all the necessary tests for the diagnosis of these patients is beyond the scope of 
this chapter, but there are a number of important considerations that must be taken into 
account: 
- A CT yields better performance than X-ray in pulmonary infections (Sahuquillo-Arce & 
Menéndez-Villanueva, 2010). 
- Infections of the digestive tract can be misleading and may be interpreted as an 
Ulcerative Colitis relapse. It may require tissue biopsy for microbiological and 
histopathological studies, as well as all the usual non-invasive tests such as stool 
culture, study of parasites or detection of C. difficile toxins. 
- Central nervous system infections may require a MRI or even a biopsy, especially if 
space-occupying lesions are observed. 
3.3 Opportunistic microorganisms and common infectious agents 
The following is a brief description of the most frequent opportunistic microorganisms 
found in immunosuppressed patients; but we will also discuss about typical pathogens that 
may have a ominous prognosis chiefly due to the poor immune system of the host (Murray 
et al., 2003; Rahier et al., 2009). 
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3.3.1 Bacteria 
These microorganisms constitute the commonest group of infectious agents in both 
gastrointestinal and other systems infections. Three different groups can be distinguished:  
- Nosocomial infections by pathogens that may present antimicrobial multi-resistance 
such as Pseudomonas aeruginosa. 
- Community-acquired microorganisms which, in these patients, may be more 
devastating and with greater tendency to spread, such as Streptococcus pneumoniae. 
- Endogenous microorganisms which were under control before immunosuppression 
(Qu et al., 2009).  
The following are the most relevant of bacterial pathogens, both common and opportunistic. 
Recommended treatments for opportunistic and common bacterial pathogens are shown in 
table 2. 
- Pseudomonas aeruginosa is a Gram-negative rod found in nature, which colonizes the 
hospital setting. Among the many virulence factors it has, adhesion to the epithelium, 
toxin production, biofilm formation and quorum sensing are essential for its great 
adaptation and survivability. This bacterium is associated with nosocomial infections, 
mechanical ventilation infection, wound infections and community-acquired 
pneumonia, chiefly in immunosuppressed patients who have been in contact with the 
hospital environment. The most challenging infection is pneumonia, as it is rapidly 
progressive and radiographically indistinguishable from other pyogenic infections. 
Patients present with productive cough, fever, dyspnoea, micro-abscesses and focal 
haemorrhage. Mortality is very high among immunosuppressed patients because of 
its rapid course, it reaches up to 40%, and this ratio increases if there is bacteraemia. 
Antimicrobial treatment is problematic because of its intrinsic resistance to many 
broad-spectrum antibiotics, especially considering that hospital-acquired strains 
present a greater number of resistances due to selection in a hostile antimicrobial 
environment. 
- Staphylococcus aureus is a Gram-positive coccus that colonizes the skin and is a major 
nosocomial pathogen. Between 10-40% of people are nasal carriers. It has several 
virulence factors, including toxin production and antibiotic resistance. Methicillin 
resistant strains (MRSA) vary in proportion between countries (2% in the Netherlands, 
28% in Spain, 54% in Portugal). It is more frequent in hospitals and health-care 
associated settings. This pathogen is very versatile and can produce different clinical 
syndromes ranging from conditions like skin or surgical wound infection to 
bacteraemia, meningitis, or a highly aggressive type of pneumonia that occurs after an 
Influenzavirus infection. 
- Streptococcus pneumoniae is a Gram-positive coccus that can be found in the 
nasopharynx of healthy carriers. It is an important agent of community-acquired 
pneumonia, but it can also emerge as sinusitis, otitis, bacteraemia or meningitis. 
- Nocardia spp. is a Gram-positive partially acid-fast branched rod. Ubiquitous in the 
environment, it is acquired primarily by inhalation. Pulmonary nocardiosis supposes 
over 40% of all forms, and Nocardia asteroides complex is responsible for up to 90%. It can 
follow an acute course, but chronic forms are more likely, presenting as a recurrent 
suppurative process with or without abscess formation, cavitation, or fistula. Other 
types include surgical wound infection or disseminated forms that can affect the central 
nervous system. The prognosis depends on the patient’s immunosuppression level and 
bacterial dissemination. 
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Microorganism Treatment Alternative treatment 
Empirical 
treatment 
Amikacin + piperacillin-
tazobactam, imipenem or 
meropenem  
Empirical treatment should be 
adapted to more likely 
microoganisms, local antimicrobial 
resistance patterns and prior 
infections. 
Pseudomonas 
aeruginosa 
Ceftazidime; cefepime;  aztreonam; 
Piperacillin-tazobactam or 
carbapenem   
Associate aminoglycoside + 
ciprofloxacin or colistin in severe 
systemic infection. 
 
Staphylococcus 
aureus 
Methicilin susceptible S. aureus: 
Cloxacillin + gentamicin.  
Methicilin resistant S. aureus: 
glycopeptide.  
If vancomycin MIC is > 1 mg/l 
then linezolid or daptomycin. 
MSSA: amoxicillin-clavulanate; 
ampicillin-sulbactam;  1st-2nd 
generation cephalosporins; 
clindamycin; levofloxacin or 
moxifloxacin.  
MRSA: Linezolid; tigecycline or 
minocycline  
Listeria 
monocytogenes 
Ampicillin alone or associated with 
gentamicin 
Cotrimoxazole alone or associated 
with ampicillin or rifampicin. 
Clarithromycin, doxycycline, 
rifampicin, moxifloxacin, 
levofloxacin, meropenem, linezolid 
and vancomycin are also active 
Nocardia spp. Cotrimoxazole + amikacin, 
cefotaxime, ceftriaxone or 
imipenem.  
Linezolid; levofloxacin; 
moxifloxacin, tigecycline; 
doxycycline; minocycline or 
amoxicillin-clavulanate 
Stenotrophomonas 
maltophilia 
Cotrimoxazole + minocycline, 
tigecycline, moxifloxacin, 
levofloxacin, aztreonam, 
ceftazidime, rifampicin or colistin. 
Tigecycline; fluorquinolone or 
ceftazidime 
Acinetobacter 
baumannii 
Imipenem + sulbactam or amikacin Associate two or more of the 
following according to antibiogram: 
Tigecycline, colistin, doripenem, 
ceftazidime, doxycycline, 
minocycline piperacillin-
tazobactam, tobramycin, rifampicin 
and levofloxacin 
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Microorganism Treatment Alternative treatment 
Enterobacter spp. Carbapenem or fluoroquinolone Cefepime; Piperacillin-tazobactam; 
aminoglycosides; tigecycline; 
cotrimoxazole or colistin. 
M. tuberculosis Isoniazid+rifampicin+pyrazinamid
e for two months, then 4 months on 
isoniazid + rifampicin.  
Add ethambutol the first two 
months if high suspicion of Multi-
drug resistance. 
Ethambutol or streptomycin instead 
of pyrazinamide.  
Ethambutol + levofloxacin or 
moxifloxacin instead of isoniazid. 
isoniazida + pyrazinamide + 
ethambutol for 12 months if 
rifampicin is not possible.  
Levofloxacin o moxifloxacin can be 
added the first two months. 
M. kansasii Isoniazid + rifampicin + 
ethambutol 
Amikacin; clarithromycin; 
streptomycin; fluoroquinolone or 
ethambutol if rifampicin resistance. 
Sulfamethoxazole;  linezolid or 
cycloserine can be used instead of 
ethambutol 
M. avium complex Macrolides (azithromycin  or 
clarithromycin) + ethambutol + 
rifampicin or rifabutin three times a 
week, or dialy if cavitation or 
dissemination 
Streptomycin or amikacin + 
ethambutol + rifampicin or 
ribabutin if macrolide resistance. 
Consider addition of moxifloxacin. 
Consider surgical excision in 
antimicrobial therapy failure. 
M. xenopi Isoniazid + rifampicin + 
ethambutol and/or streptomycin 
 
Table 2. Recommended treatments for bacterial pathogens in immunocompromised patients 
(Mensa et al., 2011) 
- Listeria monocytogenes is a Gram-positive rod widely distributed in the environment, 
circumstance that facilitates its incorporation into food production and processing. 
Moreover, it can grow at 4ºC and become a food-borne disease. Typically, it causes 
meningitis, encephalitis and sepsis in cell-mediated immunocompromised patients. It 
has also been linked to intestinal lesions in Ulcerative Colitis patients. 
- Legionella pneumophila is an intracellular Gram-negative rod widely distributed in 
aquatic environments. Pneumonia by this pathogen in immunocompromised patients 
can be severe and life threatening. Corticosteroid treatment is a major risk factor.   
- Nonfermentative Gram-negative bacilli and Enterobacteriaceae such as Acinetobacter 
baumannii, Stenotrophomonas maltophilia or Enterobacter spp. are increasingly becoming 
relevant as nosocomial pathogens which endanger the lives of patients during the 
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immediate postoperative period. Furthermore, these bacteria have multiple acquired 
and intrinsic antimicrobial resistances that complicate treatment. 
 
Microorganism Treatment Alternative treatment 
Escherichia coli Aminopenicillin + 
betalactamase inhibitor; 2nd- 3rd 
generation cephalosporin or 
aztreonam. 
Fosfomycin or nitrofurantoin 
can be used in urinary tract 
infections.  
Enteritis: fluoroquinolone or 
cotrimoxazole (Patients with 
enterohaemorrhagic E. coli who 
are treated can develop HUS) 
Carbapemen; tygecycline or 
colistina if Extended-Spectrum 
Betalactamase E.coli. 
 
Shigella spp. Ciprofloxacin Cotrimoxazole, ceftriaxone, 
cefixime or azithromycin 
Salmonella enterica Typhoid fever: ceftriaxone; 
cefixime or azithromycin. 
Enteritis: fluoroquinolone. 
Bacteraemia: 3rd generation 
cephalosporin; aztreonam or 
ciprofloxacin for a month. 
 
Typhoid fever: ciprofloxacin; 
aminopenicillin; chloramphenicol 
or cotrimoxazole. 
Bacteraemia: Aminopenicillin. 
 
Yersinia spp. (other 
than Y. pestis) 
Ciprofloxacin 
3rd generation cephalosporin + 
gentamicin for systemic 
infection 
Doxycycline or Cotrimoxazole 
Campilobacter jejuni Erithromycin or azithromycin Imipenem or aminopenicillin + 
betalactamase inhibitor 
Clostridium difficile Mild course: metronidazole p.o.
More aggressive forms: 
vancomycin 
Consider association with 
metronidazole i.v. or 
gammaglobulin in severe forms
Teicoplanin; fusidic acid; 
nitazoxanide; rifampicin p.o. or 
tygecycline i.v. 
Table 3. Recommended treatments for enteric bacterial pathogens in immunocompromised 
patients (Mensa et al., 2011) 
- Mycobacterium tuberculosis presents a low incidence around 2%, despite the fact that the 
risk of active tuberculosis in immunosuppressed patients is 30-50 times higher than in 
the general population. The main risk factor is reactivation of latent infection, thus 
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screening for tuberculosis before initiating therapy is required, in particular in those 
who will receive anti-Tumour Necrosis Factor alpha antibodies. In 
immunocompromised patients, M. tuberculosis is often more rapidly progressive and 
disseminates more frequently. Multi-drug resistant isolates are a worldwide concern 
that jeopardizes the final outcome. 
- Other mycobacteria such as M. kansasii, M. avium complex or M. xenopi, can appear as 
opportunistic pathogens primarily affecting the lung. They all have, in 
immunocompromised patients, an incidence similar to that of M. tuberculosis. Diagnosis 
is difficult because it requires the presence of symptoms, isolation of the microorganism 
in at least three respiratory samples and radiological signs or response to antimicrobial 
treatment. 
Recommended treatments for enteric bacterial pathogens are shown in table 3. 
- Campylobacter jejuni is a Gram-negative curve-shaped rod and the most common cause 
of community-acquired acute bacterial diarrhoea. It is normally accompanied by fever 
and abdominal pain. Campylobacter diarrhoea may contain blood or mucous. The 
majority of patients with Campylobacter diarrhoea have some component of segmental 
colitis, usually beginning in the small bowel and progressing distally to the caecum and 
colon. 
- Shigella spp. is a Gram-negative rod belonging to the Enterobacteriaceae family. It causes 
bacillary dysentery in humans, an acute recto-colitis that reflects the capacity of the 
microorganism to invade, and cause the inflammatory destruction of the intestinal 
epithelium barrier, which will disrupt the homeostatic balance that protects the gut 
against inflammation in the presence of its commensal microbiota. The activation of 
pro-inflammatory molecules can initiate an Ulcerative Colitis-like process or trigger a 
relapse (Sansonetti, 2006). 
- Adherent and invasive Escherichia coli, Salmonella enterica and Yersinia spp. all have the 
same potential as Shigella spp. to cause disease, although some serotypes of the 
Escherichia genus seem to have a healing capacity in Ulcerative Colitis patients, similar 
to that of 5-ASA drugs, by restoring mucosal homeostasis (Sartor & Muelhbauer, 2007). 
All three can cause life-threatening disease, but E. coli is much more frequent and 
versatile. 
- Clostridium difficile is a Gram-positive anaerobic rod that produces two toxins -named A 
and B- with cytopathic effects. It has been associated with Ulcerative Colitis onset and 
can also worsen its clinical manifestations or mimic an acute flare. Unlike healthy 
persons, colitis in immunocompromised patients is mostly community-acquired. 
3.3.2 Fungi 
This group represents a constellation of opportunistic pathogens associated with high 
mortality. One of the main reasons is that they are often overlooked due to its difficult and 
intricate diagnosis. Recommended treatments for fungi are shown in table 4. 
- Aspergillus spp. is a filamentous fungus present in the environment and generates high 
concentrations of spores in the air. It is not a common pathogen in healthy people since 
the inhaled spores are eliminated by the mucociliary apparatus of the respiratory tract, 
alveolar macrophages or neutrophils. But, it poses a serious challenge to neutropenic 
patients. Neutropenia and impaired cellular immunity are predisposing factors for 
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colonization and development of invasive pulmonary aspergillosis. The most 
frequently isolated species in humans are A. fumigatus (73%) and A. flavus (15%), 
followed to a lesser extent by A. niger, A. terreus, and so on. The incidence of this 
disease in immunosuppressed patients varies between 1-15%, and although there are 
limited data in patients with Ulcerative Colitis, case reports do exist that reflect its 
severity. The classic symptoms of invasive pulmonary aspergillosis are dyspnoea, chest 
pain and haemoptysis, even though 25% of patients may be asymptomatic at the time of 
diagnosis. A chest radiograph may be normal in up to 10% of cases, so CT is essential 
for diagnosis. Initially, one or more nodules with or without cavitation are detected. 
The presence of halo sign indicates vascular invasion by the microorganism, but other 
fungi such as Fusarium or diseases such as carcinomatous metastases can produce 
similar patterns. The aetiological diagnosis is based on direct examination and culture 
of non-invasive or invasive respiratory specimens such as sputum, bronchial aspirate or 
bronchoalveolar lavage, and the detection in blood or bronchoalveolar lavage of DNA 
or galactomannan, an antigen from the cell-wall of Aspergillus. Treatment is based on 
the administration of antifungals, the reconstitution of the immune status and surgery if 
it presents with severe haemoptysis, persistence of the organism despite treatment, or 
committed major vascular structures. 
- Pneumocystis jiroveci is a non-filamentous fungus that colonizes the respiratory 
epithelium of humans and is transmitted by air from person to person. Recent studies 
suggest that the reservoir comprises young children and immunocompromised 
patients. In all cases, over 90% of patients have received continued treatment with 
corticosteroids. The typical presentation is the emergence of non-productive cough, 
fever, dyspnoea and tachypnoea in a one-week period time. X-ray shows a bilateral 
interstitial pattern, but may be normal in up to 20% of cases, CT being more sensitive. 
The most informative samples for diagnosis are the bronchoalveolar lavage and 
transbronchial biopsy, but induced sputum, nasopharyngeal washings or biopsies are 
also useful. Prophylaxis is not as clear as in HIV-positive patients, but is recommended 
in subjects who have received prolonged treatment with corticosteroids, or who have 
received anti-T cell therapy, those suffering from a prolonged neutropenia or have a 
CMV lung infection, and those with prior P. jiroveci or other opportunistic pathogens 
pneumonia. 
- Cryptococcus neoformans is a yeast widely distributed in nature which is acquired by 
inhaling small dried forms of the microorganism. In immunosuppressed patients, it is 
capable of a rapidly progressive pulmonary infection with spread to other organs, 
with great predilection for central nervous system. The most common symptoms are 
fever, pleurisy, dyspnoea, chronic cough, haemoptysis and weight loss. Neurological 
manifestations such as sub-acute meningitis with possible development of 
hydrocephalus may precede pulmonary symptoms. Chest X-rays shows calcified 
nodules, bilateral infiltrates and hilar or mediastinal lymphadenopathy, cavitation 
and pleural effusion may also be observed. The aetiological diagnosis is done through 
the vision of encapsulated yeasts in respiratory samples or cerebrospinal fluid, 
cultivation and identification by biochemical tests. Detection and titration of capsular 
antigen in cerebrospinal fluid, blood or respiratory specimens facilitate an early 
diagnosis, but it is also useful to acknowledge the disease prognosis and progression. 
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Prophylaxis with fluconazole is not recommended because of the low incidence of 
this disease. 
- Candida spp. is a yeast that frequently colonizes the respiratory and gastrointestinal 
tracts of immunosuppressed patients or of those who have received broad spectrum 
antibiotics. It seldom causes disease but it may arise as oral mucositis, colonization of 
catheters and surgical wounds, and even as haematogenous dissemination. Diagnosis 
may be difficult in some cases because it is necessary to distinguish between 
colonization and infection. Prophylaxis with fluconazole in different 
immunocompromised patients has led to increasing numbers of antifungal resistant 
strains of Candida other than C. albicans, such as C. glabrata or C. krusei. 
- Histoplasma capsulatum is endemic along the Ohio, Mississippi and St. Lawrence rivers, 
but it can be found throughout the world. Histoplasmosis can reactivate years after 
primary infection and may mimic tuberculosis or neoplastic disease chiefly in the 
nervous central system and mucocutaneous surfaces. 
 
Microorganism Treatment Alternative treatment 
Empirical Caspofungin or voriconazole Amphotericin B lipid formulation  
Aspergillus spp. Voriconazole  
Combination with equinocandine is 
recommended  
Withholding immunosuppressive 
treatment and surgical excision 
should be considered 
Caspofungin; amphotericin B lipid 
formulation or the combination of 
both. 
Pneumocystis 
jiroveci 
Cotrimoxazole Pentamidin; clindamycin + 
primaquine; dapsone + 
trimethoprim; atovaquone 750 
mg/8 h. 
Cryptococcus 
neoformans 
Amphotericin B + flucytosine  Fluconazole + flucytosine 
Candida spp. Equinocandine (except for C. 
parapsilosis and C. guilliermondii); 
fluconazole (except for C. krusei or 
C. glabrata) 
Voriconazole or amphotericin  
Table 4. Recommended treatments for fungal pathogens in immunocompromised patients 
(Mensa et al., 2011) 
3.3.3 Viruses 
Viruses are a group of pathogens whose incidence is increasing and may have a high 
morbidity and mortality. Disease in these patients may be community-acquired, but 
reactivation of latent viruses such as Herpesviridae is more characteristic and challenging. 
Recommended treatments for common viruses are shown in table 5. 
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- Cytomegalovirus is a herpes virus that remains in a latent form after primary infection. 
The disease is acquired by infection from another person or by reactivation after 
immunosuppressive therapy. CMV colitis can imitate an Ulcerative Colitis flare. 
Symptoms range from fever and abdominal pain to haemorrhagic diarrhoea or 
fulminant colitis. Moreover, it has been associated with steroid-resistant Ulcerative 
Colitis (Ayre et al., 2009). Pneumonitis is also a major complication; radiologically, it 
shows interstitial or bilateral reticulonodular infiltrates. CT shows bronchial wall 
thickening and ground-glass opacification. In addition to infectious conditions, CMV 
produces local immunosuppression that promotes super-infection with other 
opportunistic pathogens. The presence of CMV in the lung is a risk factor for infection 
with Aspergillus or Pneumocystis jiroveci. The etiological diagnosis is complicated by the 
presence of co-infection and similarity with other pathogens. Interestingly, the 
histopathological detection of CMV means infection, but not necessarily disease. The 
most predictive diagnosis is achieved with the detection of CMV in blood either by cell 
cultures (shell vial + immunofluorescence staining), detection of pp65 antigen in 
peripheral blood leukocytes, or detection of viral load with molecular biology 
techniques (PCR, real-time PCR). 
 
Microorganism Treatment Alternative treatment 
Citomegalovirus Ganciclovir Foscarnet  or cidofovir 
 
Varicella-Zoster virus Valaciclovir; acyclovir or 
famciclovir 
Foscarnet 
Herpes simplex virus Acyclovir  Foscarnet or cidofovir 
Herpes 8 virus Unknown Foscarnet; cidofovir; adefovir; 
valaciclovir or ganciclovir  
Epstein-Barr virus Acyclovir or ganciclovir  
Respiratory sincitial virus Inhaled ribavirin 
Consider association with 
palivizumab 
 
Influenzavirus  Oseltamivir or zanamivir Amantadine or ribavirin (in 
severe pneumonia by B or C 
serotypes) 
Table 5. Recommended treatments for viral pathogens in immunocompromised patients 
(Mensa et al., 2011) 
- Respiratory syncytial virus is a seasonal pathogen that affects mostly in winter and 
spring. It may cause pneumonitis on its own or alonside other opportunistic 
microorganisms with similar clinical and radiological findings (CMV, P. jiroveci). Thus, 
suspicion is essential for diagnosis. Prevention is the best therapeutic tool because, 
although there are treatments with ribavirin or monoclonal antibodies, the results are 
yet inconclusive. 
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- Herpes simplex virus, immunosuppressed patients frequently develop symptomatic HSV 
disease which can be life-threatening. Undoubtedly, disseminated HSV with 
pulmonary, hepatic, colonic or brain involvement have a very high mortality rate. Early 
treatment reduces mortality and morbidity. 
- Varicella-Zoster virus primary infection in immunocompromised patients can develop 
pneumonia or encephalic complications. Reactivation of the virus presents the risk of 
disseminated zoster, with mortality rates similar to those for varicella. 
- Epstein-Barr virus can reactivate in patients on immunosuppressive therapy and, 
although the clinical relevance has not yet been established, its capability to produce 
lymphomas demands careful attention. Cessation of immunosuppressive agents often 
leads to lymphoma spontaneous regression. 
- Herpes 8 is not a very common pathogen, although colonic Kaposi’s sarcoma that 
required total colectomy has been described in an Ulcerative Colitis patient under 
immunosuppressive therapy. 
- There is little evidence about Hepatitis C virus and Ulcerative Colitis, but 
immunotherapy does not seem to have any adverse effect on its course. Nevertheless, 
liver function and viraemia must be monitored as well as patient’s immunosuppression 
level in order to make a decision on treatment. 
- Corticosteroids and anti-Tumour Necrosis Factor alpha appear to have a deleterious 
effect on Hepatitis B virus-positive patients. Consequently, prophylactic antiviral 
treatment should be started prior to immunosuppressive therapy.  
- HIV-positive patients on immunosuppressive therapy should be closely observed due 
to their underlaying condition. Although the interactions between these diseases fall 
beyond the scope of this chapter, doctors should be very cautious and suspend 
immunosuppressive therapy if concomitant opportunistic infections arise or there is no 
response to Highly Active Anti Retroviral Therapy. 
- Other respiratory viruses such as Influenza, Parainfluenza, Metapneumovirus and 
Adenovirus, are a growing cause of morbidity and mortality in immunocompromised 
patients, reaching 10-20% of all pulmonary infections in some studies. The course of 
infection may also be aggravated by Haemophilus influenzae, Streptococcus pneumoniae or 
Staphylococcus aureus bacterial pneumonia (Sahuquillo-Arce & Menéndez-Villanueva, 
2010). 
3.4 Parasites 
They are a group of rare lung infections, but physicians must be observant due to its 
remarkable clinical relevance. Recommended treatments for common parasites are shown in 
table 6. 
- Strongyloides stercoralis is an intestinal nematode of tropical and subtropical climates. 
The larvae penetrate the skin and migrate via the blood to the lungs, from where they 
will reach the intestine. In immunosuppressed patients, it can produce Ulcerative 
Colitis-like colitis but also hyperinfestation which implies very poor prognosis since 
diffuse bronchopneumonia and alveolar bleeding can be present. The diagnosis is done 
by observing larvae in faecal extensions, but also in the sputum or bronchoalveolar 
lavage from hyperinfestation cases. 
- Toxoplasma gondii is a parasite of cats. It rarely causes disease in healthy patients, but it 
remains dormant and can reactivate in immunosuppressed patients. Toxoplasmosis is 
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usually due to reactivation, and commonly causes central nervous system disease 
which is uniformly fatal if untreated, but also interstitial pneumonia, haemorrhagic 
pneumonia, lung consolidation, myocarditis or chorioretinitis. The high mortality 
observed is related to diagnosis delay. The diagnosis of choice is the direct view of the 
parasite by histological staining or isolation in cell cultures. 
- Leishmania spp. are obligate intracellular protozoa transmitted to humans from infected 
sandflies. In visceral leishmaniasis, the parasite migrates to the internal organs such as 
liver, spleen and bone marrow. Signs and symptoms include fever, weight loss, malaise, 
anaemia, substantial swelling of the liver and spleen, and frequently, diarrhoea. 
Visceral leishmaniasis is a zoonosis rare in Western Europe, but life-threatening in 
immunocompromised patients. The course of infection depends on the type of the 
patient’s immune reaction; patients with Th 1 response often present an asymptomatic 
or oligo-symptomatic disease, and after recovery they are immune to re-infection 
(Badaró et al., 1986; Hagenah et al., 2007). The disease can relapse after treatment in 
immunocompromised patients. 
 
Microorganism Recommended treatment Alternative treatment 
Toxoplasma 
gondii 
sulfadiazine + 
pyrimethamine + folinic 
acid  
Pregnant woman:  
spiramycin until delivery 
Cotrimoxazole;  clindamycine + 
pyrimethamine + folinic; pyrimethamine + 
folinic acid + dapsone, atovacuona or 
clarithromycin; sulfadiazine + atovaquone, 
dapsone or clarithromycin. 
Strongyloides 
stercoralis 
Ivermectin for 5-7 days  
Consider addition of 
albendazole in 
hyperinfestation 
Albendazole (once every month during 3 
months after  therapeutic success) 
Thiabendazole or mebendazole  
Leishmania spp. Amphotericin B liposomal 
on days 1, 5, 10, 17, 24, 31 
and 38 
Pentamidine; meglumine antimoniate; 
amphotericin B deoxycholate or 
paramomicin 
Table 6. Parasitic infections treatment in immunocompromised patients (Mensa et al., 2011) 
4. Conclusions 
The relationship between the microbiota and its host is based on a very delicate equilibrium. 
Recent research has enlarged our knowledge about the interactions between humans and 
microbiota to an extent that admiration is the only possible reply at the sight of all the 
associations and its connotations. Trillions of microorganisms live and interact inside our 
bodies, and they are not only useful, but valuable for us.  
Immune responses are modulated in such a fine way as to differentiate beneficial 
microorganisms from pathogens, and this happens at every moment without even noticing. 
As we have seen, in normal circumstances different bacteria play different roles; some have 
pro-inflammatory faculties, others protect from inflammation and at least one, Candidatus 
arthromitus, can have both. In the end, the microbiota and the immune system achieve a 
balance that preserves intestinal homeostasis. But, when the barrier between the two worlds 
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fails, this cross-talk between bacteria and immune cells is disturbed and inflammation 
reactions take place.  
The involvement of bacteria in Ulcerative Colitis is not yet utterly understood, but 
unquestionably, microorganisms found in gut microbiota have the potential to induce and 
maintain inflammatory processes. Needless is to say that more research is needed, but the 
picture drawn so far brings to light that, interestingly, the human microbiota could be both 
the cause and the solution to this disease. 
While a total comprehension of the aetiopatholgy is found so an accurate cure may be 
developed, Ulcerative Colitis patients are treated with immunosuppressive drugs. This fact 
involves that their immune response against challenging microorganisms are impaired. 
Thus they are exposed to infectious diseases with a worst course and prognosis, but also to 
opportunistic pathogens. A better knowledge and awareness about this scenario is 
necessary by both doctors and patients for a correct and early management of infection. On 
the other hand, specialist in gastroenterology, internal medicine, microbiology and 
infectious diseases need to collaborate for a successful management of these patients. 
In conclusion, Ulcerative Colitis, due to the intrinsic characteristics of the patient and 
immunosuppressive therapies, features a multifaceted relationship with microorganisms 
which we are just beginning to unveil. 
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